Merck Group appoints head of global procurement

Friedheim Felten takes up role on 1 April

Friedhelm Felten is to become head of corporate procurement, taking over responsibility for the global purchasing activities of the Merck Group.

Taking up the role on 1 April, Felten succeeds Friedrich Schmitt, who has headed the function since 1997 and will be retiring at the end of July. Felten will report to Michael Becker, chief financial officer.

Corporate procurement is responsible for purchasing production materials such as pharmaceutical raw materials and chemicals, and for procuring technical components such as production and laboratory equipment as well as services such as pharmaceutical research and development. The 500 members of the global matrix organisation handle an annual purchasing volume of around b4.5bn.

Felten joined Merck in July 2009 as head of procurement for Services. He has many years of management experience in purchasing and in other functions at international companies, including DHL Global Forwarding in Singapore, DHL Logistics in London, and BASF AG in Ludwigshafen, as well as various BASF subsidiaries in Asia.

You may also like

Manufacturing

CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex

Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Manufacturing

Vetter strengthens senior management team for growth

Three new managing directors to support global sustainable development
Finance

Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines

The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
Research & Development

Syncona launches early-stage drug development company, Slingshot Therapeutics

The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
Manufacturing

Ascend Advanced Therapies expands US footprint through Advanced BioScience Laboratories merger

Ascend's collaboration with EW Healthcare partners will expand its reach in the US pharmaceutical market through capital investment and an uptick in GMP AAV manufacturing capacity
Manufacturing

AstraZeneca invests $3.5bn into its US pharmaceutical research and manufacturing capabilities

The company will expand its biologics manufacturing, as well as its speciality manufacturing and cell therapy production capacity, while also extending its pharmaceutical research and development capabilities through this investment
Subscribe now